Brief Research Report

Published on 19 May 2023

Enhancing immune protection against MERS-CoV: the synergistic effect of proteolytic cleavage sites and the fusion peptide and RBD domain targeting VLP immunization

in Vaccines and Molecular Therapeutics

Jeein Oh
Uni Park
Juhyung Kim
Kyeongseok Jeon
Chulwoo Kim
Nam-Hyuk Cho
Youn Soo Choi

Frontiers in Immunology

doi 10.3389/fimmu.2023.1201136

2,411 views
1 citation

Original Research

Published on 19 May 2023

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement

in Vaccines and Molecular Therapeutics

Qier Chen
Rong Li
Bolin Wu
Xu Zhang
Hui Zhang
Ran Chen

Frontiers in Immunology

doi 10.3389/fimmu.2023.1193175

4,899 views
7 citations

Original Research

Published on 18 May 2023

Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces B. pertussis nasal colonization

in Vaccines and Molecular Therapeutics

Kacy S. Yount
Jesse M. Hall
Kyle Caution
Mohamed M. Shamseldin
Myra Guo
Keirsten Marion
Audra R. Fullen
Yimin Huang
Jennifer A. Maynard
Sally A. Quataert

Frontiers in Immunology

doi 10.3389/fimmu.2023.1181876

3,739 views
8 citations

Original Research

Published on 18 May 2023

Production of monoclonal antibody of heat-labile toxin A subunit to identify enterotoxigenic Escherichia coli by epitope mapping using synthetic peptides

in Vaccines and Molecular Therapeutics

Jun-Young Park
Seung-Hak Cho

Frontiers in Immunology

doi 10.3389/fimmu.2023.1152910

1,714 views

Original Research

Published on 17 May 2023

Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population

in Vaccines and Molecular Therapeutics

Sina Hosseinian
Rafael de Assis
Ghali Khalil
Madeleine K. Luu
Aarti Jain
Peter Horvath
Rie Nakajima
Anton M. Palma
Anthony Hoang
Eisa Razzak

Frontiers in Immunology

doi 10.3389/fimmu.2023.1166261

1,834 views
6 citations

Original Research

Published on 17 May 2023

Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

in Vaccines and Molecular Therapeutics

Huanhuan Cao
Yufei Huang
Chunxiu Zhong
Xingmei Liao
Wenjuan Tan
Siru Zhao
Liangxu Guo
Rong Fan

Frontiers in Immunology

doi 10.3389/fimmu.2023.1167533

1,878 views
3 citations

Review

Published on 15 May 2023

Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy

in Vaccines and Molecular Therapeutics

Susanna Esposito
Gayatri Amirthalingam
Matteo Bassetti
Francesco Blasi
Francesco Giuseppe De Rosa
Natasha B. Halasa
Ivan Hung
Albert Osterhaus
Tina Tan
Juan Pablo Torres

Frontiers in Immunology

doi 10.3389/fimmu.2023.1162342

9,448 views
12 citations

Original Research

Published on 15 May 2023

Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine

in Vaccines and Molecular Therapeutics

Erika Petro-Turnquist
Matthew Pekarek
Nicholas Jeanjaquet
Cedric Wooledge
David Steffen
Hiep Vu
Eric A. Weaver

Frontiers in Immunology

doi 10.3389/fimmu.2023.1143451

3,890 views
8 citations

Original Research

Published on 12 May 2023

Biomarkers detected in cord blood predict vaccine responses in young infants

in Vaccines and Molecular Therapeutics

Carolyn H. Baloh
Guglielmo M. Venturi
Bernard M. Fischer
Liane S. Sadder
Julie J. Kim-Chang
Cliburn Chan
Kristina De Paris
Li Yin
Grace M. Aldrovandi
Maureen M. Goodenow

Frontiers in Immunology

doi 10.3389/fimmu.2023.1152538

2,850 views
3 citations

Review

Published on 12 May 2023

Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective

in Vaccines and Molecular Therapeutics

Narges Ebrahimi
Zahra Yousefi
Gholamreza Khosravi
Fatemeh Eskandari Malayeri
Marjan Golabi
Monireh Askarzadeh
Mohammad Hossein Shams
Behrooz Ghezelbash
Nahid Eskandari

Frontiers in Immunology

doi 10.3389/fimmu.2023.1150238

15,724 views
38 citations

Brief Research Report

Published on 12 May 2023

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao

in Vaccines and Molecular Therapeutics

Hoi Man Ng
Chon Lok Lei
Siyi Fu
Enqin Li
Sek In Leong
Chu Iong Nip
Nga Man Choi
Kai Seng Lai
Xi Jun Tang
Chon Leng Lei

Frontiers in Immunology

doi 10.3389/fimmu.2023.1131985

1,968 views
2 citations

Original Research

Published on 12 May 2023

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

in Vaccines and Molecular Therapeutics

Ralph Adams
Callum Joyce
Mikhail Kuravskiy
Katriona Harrison
Zainab Ahdash
Matthew Balmforth
Kelda Chia
Cinzia Marceddu
Matthew Coates
James Snowden

Frontiers in Immunology

doi 10.3389/fimmu.2023.1170357

5,984 views
10 citations

Perspective

Published on 12 May 2023

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development

in Vaccines and Molecular Therapeutics

Zuben E. Sauna
Vibha Jawa
Sathy Balu-Iyer
Narendra Chirmule

Frontiers in Immunology

doi 10.3389/fimmu.2023.1151888

4,122 views
6 citations

Original Research

Published on 12 May 2023

A novel precision-serology assay for SARS-CoV-2 infection based on linear B-cell epitopes of Spike protein

in Vaccines and Molecular Therapeutics

Samuel B. Lundin
Hanna Kann
Alma Fulurija
Björn Andersson
Sravya S. Nakka
Lars-Magnus Andersson
Magnus Gisslén
Ali M. Harandi

Frontiers in Immunology

doi 10.3389/fimmu.2023.1166924

1,869 views
2 citations

Review

Published on 10 May 2023

New tools for immunologists: models of lymph node function from cells to tissues

in Vaccines and Molecular Therapeutics

Tochukwu Ozulumba
Alyssa N. Montalbine
Jennifer E. Ortiz-Cárdenas
Rebecca R. Pompano

Frontiers in Immunology

doi 10.3389/fimmu.2023.1183286

9,381 views
14 citations

Editorial

Published on 05 May 2023

Editorial: Non-reactogenic vaccines against Q-fever

in Vaccines and Molecular Therapeutics

Anthony E. Gregory
D. Huw Davies

Frontiers in Immunology

doi 10.3389/fimmu.2023.1196522

1,510 views

Navigation group

Articles

Enhancing immune protection against MERS-CoV: the synergistic effect of proteolytic cleavage sites and the fusion peptide and RBD domain targeting VLP immunization

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement

Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces B. pertussis nasal colonization

Production of monoclonal antibody of heat-labile toxin A subunit to identify enterotoxigenic Escherichia coli by epitope mapping using synthetic peptides

Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population

Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy

Adenoviral-vectored epigraph vaccine elicits robust, durable, and protective immunity against H3 influenza A virus in swine

Biomarkers detected in cord blood predict vaccine responses in young infants

Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development

A novel precision-serology assay for SARS-CoV-2 infection based on linear B-cell epitopes of Spike protein

New tools for immunologists: models of lymph node function from cells to tissues

Editorial: Non-reactogenic vaccines against Q-fever